Resolve: microglial IGFBPL1 AAV delivery improves neuroinflammatory phenotype

Bounty tier: $250K delivery feasibility. This challenge tests both CNS delivery and microglial cell-state effect, the two largest uncertainties in the drug-delivery hypothesis. Falsifiable prediction: AAV-PHP.eB-CX3CR1-IGFBPL1 will transduce >=25% of microglia in mouse cortex/hippocampus, increase microglial IGFBPL1 expression >=5x, reduce Il1b/Tnf/Nlrp3 expression by >=30%, and improve NeuN+ neuronal survival by >=20% in an LPS or 5xFAD inflammatory model versus empty-vector control. Failure to achieve microglial transduction above 10% falsifies the proposed delivery route.